DIA conducted a study in collaboration with the Tufts Center for the Study of Drug Development (CSDD) and found that 65 percent of pharmaceutical and biotech companies surveyed are investing in patient-centric initiatives in drug development.
Reported benefits include: reduced screen failure rates, faster patient recruitment, improved subject retention, reduced protocol amendments, and a greater number of patient relevant endpoints. In the study, cost to conduct, ease of conducting, and reported impact were measured.
Tools and resources included in the DIA Patient Engagement Study Findings:
- Executive Summary of the study results and key insights
- Considerations Guide to implementing patient-centric initiatives